Small molecule
5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and energy homeostasis. It has been promoted in biohacking and fitness communities as 'exercise in a pill' based on preclinical studies showing reversal of diet-induced obesity in mice. There are no published human clinical trials. The compound is not FDA-approved for any indication and is sold only as a research chemical.
Clearly state the preclinical-only evidence base. No human trials exist. Do not publish dosing protocols or sourcing instructions. Track 'exercise in a pill' claims against the actual preclinical data.
A foundational study showed that NNMT knockdown protects against diet-induced obesity in mice by increasing energy expenditure, establishing NNMT as a therapeutic target (Kraus et al., Nature, 2014).
Selective and membrane-permeable small molecule NNMT inhibitors, including 5-amino-1MQ, were shown to reverse high-fat diet-induced obesity in mice by increasing energy expenditure and reducing fat mass (Neelakantan et al., Biochem Pharmacol, 2018).
No human clinical trials of 5-amino-1MQ have been published as of the review date. All efficacy claims are based on preclinical (mouse) data only.
5-Amino-1MQ is not FDA-approved for any indication and is available only as a research chemical. The compound has not undergone regulatory safety review for human use.
Evidence level: Community discussion
Sources: PubMed / NCBI, PubMed / NCBI
Track these claims without endorsing them. The 'exercise in a pill' framing is a marketing/biohacking characterization, not a clinical or scientific claim. Evidence is exclusively from mouse models.
Evidence level: Preclinical
Sources: PubMed / NCBI, PubMed / NCBI
Cite the Neelakantan et al. 2018 paper directly. Results are from mouse studies only. No human pharmacokinetic, safety, or efficacy data exist. Do not extrapolate to humans.
Evidence level: Primary regulatory
Sources: PubMed / NCBI
Confirmed via PubMed search. Update if human trials are registered or published. The absence of human data is a critical safety consideration.
Source records are stored in the repo and linked from each claim.
Metformin is an FDA-approved biguanide antidiabetic (marketed as Glucophage and generics) used as first-line therapy for...
Evidence reviewMethylene blue (methylthioninium chloride) is an FDA-approved medication (trade names Provayblue, Proveblue) for the tre...
Regulatory watchRapamycin (sirolimus) is an FDA-approved mTOR inhibitor (marketed as Rapamune) used to prevent organ transplant rejectio...
Evidence review